Sanofi/Regeneron Innovation Award 2025

Sanofi/Regeneron Innovation Award:
Novel Approaches in Type 2 Inflammation

With this award, Sanofi and Regeneron support residents and senior physician, who are clinically active in allergology/clinical immunology in Switzerland and whose translational scientific work deals with the topic of type 2 inflammation and related diseases.

The award is endowed with 15’000 CHF and is intended for the execution of a scientific project.

Type 2 inflammation plays an important role in a number of immune-mediated inflammatory diseases in allergology, dermatology, gastroenterology and respiratory medicine. The underlying inflammatory mechanisms are complex and the disease burden for patients and their families is high. Although our understanding of the mechanisms of type 2 inflammation has increased in recent years, many questions remain unanswered. Sanofi and Regeneron have established this science innovation award to promote independent translational scientific research in the field of type 2 inflammation in Switzerland.

The prize is aimed at all residents and senior physicians, working in allergology/clinical immunology, who would like to submit exciting research projects on the topic of type 2 inflammation that are being carried out in Switzerland. The submitted proposals can address ongoing projects and master or doctoral theses in the field of allergology/clinical immunology advancing this research. The submitted projects will be judged and awarded by an independent jury of experts from the Swiss Society of Allergology and Immunology (SSAI). The award ceremony will take place at the SGAI Annual Meeting 2025 in Lausanne.

Please submit your projects using the Award Submission Form to the SSAI Office (Jolanda Trachsel, General Manager SGAI, email: office@ssai.ch) by 31.07.2025 at the latest.